Cervical Cancer Screening by Visual Inspection and HPV Testing in Eswatini

Overview

Journal Prev Med

Specialty Public Health

Date 2022 Jul 10

PMID 35810934

Authors

Themba G Ginindza

Mathilde Forestier

Maribel Almonte

Affiliations

Soon will be listed here.

Abstract

In 2009, visual inspection with acetic acid (VIA) followed by cryotherapy (VIA-and-cryotherapy), was introduced into the Eswatini cervical cancer prevention programme. We present screening results of 654 women attending VIA-and-cryotherapy who participated in a sexually transmitted infections prevalence study, at which samples for HPV DNA testing and liquid-based cytology (LBC) were also collected. VIA positives (VIA+) ineligible for cryotherapy, suspected cancers and women with high-grade squamous intraepithelial or worse lesions (HSIL+) on LBC were referred for diagnosis and treatment. Women with negative VIA who were HPV positive (HPV+) and those VIA+ treated with cryotherapy were recalled for another VIA one-year later. The positivity rates of VIA, HPV, atypical squamous cells of undetermined significance or worse cytology abnormalities (LBC ASCUS+) and low-grade squamous intraepithelial or worse lesions (LBC LSIL+) were 9.7%, 42.6%, 13.2% and 5.3%, respectively. HPV testing detected 29 of 31 LSIL+ (93.6%, 95%CI: 78.6-99.2) while VIA only detected 11 (35.6%, 95%CI: 19.2-54.6). The HIV prevalence was 43% (95%CI: 39.2-46.9). HIV positives were at increased risk of being VIA+ (age-adjusted odds ratio: 2.5, 95%CI: 1.5-4.3), HPV+ (3.7, 2.6-5.3) and having LSIL+ (16.3, 4.9-54.8). The ineligibility rates for cryotherapy were 38% (24 of 63 VIA+), and 46% among HIV positives (18 of 39 VIA+). HPV testing was substantially more sensitive than VIA, thus, HPV followed by ablative treatment may be more effective. However, the high ineligibility for cryotherapy highlights the need for improving the assessment of eligibility for ablative treatment and for strengthening colposcopy, particularly in populations with high HIV prevalence.

References

Wentzensen N, Chirenje Z, Prendiville W . Treatment approaches for women with positive cervical screening results in low-and middle-income countries. Prev Med. 2021; 144:106439. DOI: 10.1016/j.ypmed.2021.106439. View

Looker K, Ronn M, Brock P, Brisson M, Drolet M, Mayaud P . Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc. 2018; 21(6):e25110. PMC: 5989783. DOI: 10.1002/jia2.25110. View

Brisson M, Kim J, Canfell K, Drolet M, Gingras G, Burger E . Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395(10224):575-590. PMC: 7043009. DOI: 10.1016/S0140-6736(20)30068-4. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Almonte M, Ferreccio C, Luciani S, Gonzales M, Delgado J, Santos C . Visual inspection after acetic acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru. PLoS One. 2015; 10(1):e0115355. PMC: 4312028. DOI: 10.1371/journal.pone.0115355. View

De Vuyst H, Lillo F, Broutet N, Smith J . HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008; 17(6):545-54. DOI: 10.1097/CEJ.0b013e3282f75ea1. View

Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2019; 8(2):e191-e203. PMC: 7025157. DOI: 10.1016/S2214-109X(19)30482-6. View

Okonda S, Wright C, Michelow P . The status of cervical cytology in Swaziland, Southern Africa: a descriptive study. Cytojournal. 2009; 6:14. PMC: 2758303. DOI: 10.4103/1742-6413.54916. View

Bicego G, Nkambule R, Peterson I, Reed J, Donnell D, Ginindza H . Recent patterns in population-based HIV prevalence in Swaziland. PLoS One. 2013; 8(10):e77101. PMC: 3797108. DOI: 10.1371/journal.pone.0077101. View

10.

Gage J, Rodriguez A, Schiffman M, Garcia F, Long R, Budihas S . Treatability by cryotherapy in a screen-and-treat strategy. J Low Genit Tract Dis. 2009; 13(3):174-81. PMC: 2735767. DOI: 10.1097/LGT.0b013e3181909f30. View

11.

Smith-McCune K, Shiboski S, Chirenje M, Magure T, Tuveson J, Ma Y . Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One. 2010; 5(4):e10094. PMC: 2851652. DOI: 10.1371/journal.pone.0010094. View

12.

Solomon D, Davey D, Kurman R, Moriarty A, OConnor D, Prey M . The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287(16):2114-9. DOI: 10.1001/jama.287.16.2114. View

13.

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

14.

Ginindza T, Dlamini X, Almonte M, Herrero R, Jolly P, Tsoka-Gwegweni J . Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland. PLoS One. 2017; 12(1):e0170189. PMC: 5256897. DOI: 10.1371/journal.pone.0170189. View